Myastad (Mycophenolic Acid)

Mycophenolic Acid works by selectively inhibiting the enzyme inosine monophosphate dehydrogenase, which is essential for the synthesis of guanosine nucleotides. This blockade limits the proliferation of T‑ and B‑lymphocytes, the cells primarily responsible for adaptive immune responses, thereby providing immunosuppression.

The dose of Myastad is individualized by the prescribing clinician based on factors such as the type of transplant, the patient’s renal and hepatic function, concomitant medications, and the therapeutic goal. No fixed dosing regimen is provided here; the prescriber sets the appropriate regimen.

Myastad is classified as Pregnancy Category D, indicating evidence of risk to the fetus. It is generally not recommended for use during pregnancy unless the potential benefit justifies the risk. Breastfeeding is also discouraged because the drug can be excreted in milk and may affect the infant.

To order Myastad, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

The primary alternative to Myastad is azathioprine, another oral immunosuppressant. While both suppress lymphocyte proliferation, Myastad offers more selective inhibition of guanosine synthesis, which can result in a different side‑effect profile. Choice between them depends on efficacy, tolerability, drug interactions and individual patient factors.

Myastad should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture and direct sunlight. Do not store in a refrigerator or freezer unless otherwise specified by the manufacturer.

Myastad is taken orally, usually as a tablet or capsule, with or without food as directed by the prescriber. The exact administration schedule—such as once or twice daily—will be determined by the treating physician based on the clinical indication.

The most serious risks include bone marrow suppression (leading to anemia, leukopenia, or thrombocytopenia), severe or opportunistic infections, and worsening renal function. Patients should be monitored regularly for blood counts, signs of infection and kidney parameters, and should report any concerning symptoms promptly.

Myastad should not be used by individuals with known hypersensitivity to mycophenolic acid or any of its excipients, by pregnant women unless absolutely necessary, and by patients with uncontrolled severe infections. Caution is also advised in those with severe liver or kidney impairment, and the drug should be avoided in patients receiving live vaccines.